Kai Yang1, Fan Zhang1, Peng Han2, Zhuo-Zhong Wang1, Kui Deng1, Yuan-Yuan Zhang1, Wei-Wei Zhao1, Wei Song1, Yu-Qing Cai1, Kang Li3, Bin-Bin Cui4, Zheng-Jiang Zhu5. 1. Department of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, 150086, China. 2. Department of Colorectal Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, 150086, China. 3. Department of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University, Harbin, 150086, China. likang@ems.hrbmu.edu.cn. 4. Department of Colorectal Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, 150086, China. 13351112888@163.com. 5. Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, China. jiangzhu@sioc.ac.cn.
Abstract
INTRODUCTION: Colorectal cancer (CRC) is a clinically heterogeneous disease, which necessitates a variety of treatments and leads to different outcomes. Only some CRC patients will benefit from neoadjuvant chemotherapy (NACT). OBJECTIVES: An accurate prediction of response to NACT in CRC patients would greatly facilitate optimal personalized management, which could improve their long-term survival and clinical outcomes. METHODS: In this study, plasma metabolite profiling was performed to identify potential biomarker candidates that can predict response to NACT for CRC. Metabolic profiles of plasma from non-response (n = 30) and response (n = 27) patients to NACT were studied using UHPLC-quadruple time-of-flight)/mass spectrometry analyses and statistical analysis methods. RESULTS: The concentrations of nine metabolites were significantly different when comparing response to NACT. The area under the receiver operating characteristic curve value of the potential biomarkers was up to 0.83 discriminating the non-response and response group to NACT, superior to the clinical parameters (carcinoembryonic antigen and carbohydrate antigen 199). CONCLUSION: These results show promise for larger studies that could result in more personalized treatment protocols for CRC patients.
INTRODUCTION:Colorectal cancer (CRC) is a clinically heterogeneous disease, which necessitates a variety of treatments and leads to different outcomes. Only some CRCpatients will benefit from neoadjuvant chemotherapy (NACT). OBJECTIVES: An accurate prediction of response to NACT in CRCpatients would greatly facilitate optimal personalized management, which could improve their long-term survival and clinical outcomes. METHODS: In this study, plasma metabolite profiling was performed to identify potential biomarker candidates that can predict response to NACT for CRC. Metabolic profiles of plasma from non-response (n = 30) and response (n = 27) patients to NACT were studied using UHPLC-quadruple time-of-flight)/mass spectrometry analyses and statistical analysis methods. RESULTS: The concentrations of nine metabolites were significantly different when comparing response to NACT. The area under the receiver operating characteristic curve value of the potential biomarkers was up to 0.83 discriminating the non-response and response group to NACT, superior to the clinical parameters (carcinoembryonic antigen and carbohydrate antigen 199). CONCLUSION: These results show promise for larger studies that could result in more personalized treatment protocols for CRCpatients.
Authors: Deborah Schrag; Martin R Weiser; Karyn A Goodman; Mithat Gonen; Ellen Hollywood; Andrea Cercek; Diane L Reidy-Lagunes; Marc J Gollub; Jinru Shia; Jose G Guillem; Larissa K F Temple; Philip B Paty; Leonard B Saltz Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: David B Liesenfeld; Nina Habermann; Reka Toth; Robert W Owen; Eva Frei; Jürgen Staffa; Petra Schrotz-King; Karel D Klika; Cornelia M Ulrich Journal: Metabolomics Date: 2014-12-20 Impact factor: 4.290
Authors: Jorge A R Salvador; Vânia M Moreira; Bruno M F Gonçalves; Ana S Leal; Yongkui Jing Journal: Nat Prod Rep Date: 2012-10-09 Impact factor: 13.423
Authors: David I Rosenthal; Paul J Catalano; Daniel G Haller; Jerome C Landry; Elin R Sigurdson; Francis R Spitz; Al B Benson Journal: Int J Radiat Oncol Biol Phys Date: 2008-09-01 Impact factor: 7.038
Authors: Antonio Di Zazzo; Wei Yang; Marco Coassin; Alessandra Micera; Marco Antonini; Fabrizio Piccinni; Maria De Piano; Isabelle Kohler; Amy C Harms; Thomas Hankemeier; Stefano Boinini; Alireza Mashaghi Journal: J Mol Med (Berl) Date: 2020-04-20 Impact factor: 4.599